S trategies directed at the molecular and cellular changes in the aging cardiac vasculature may reverse the senescent predisposition for cardiovascular pathology. In younger individuals, myocardial ischemia induces the development of a collateral vasculature supply that partially protects the cardiac tissue from subsequent coronary events. [1] [2] [3] [4] However, angiogenesis and endothelial function are impaired with aging and contribute to the increased severity of cardiovascular disease in the geriatric population (for review, see Weinsaft and Edelberg 5 ). Approaches specifically aimed at restoring senescent vascular dysfunction may improve clinical outcomes of older persons with cardiovascular disease in whom present treatments are less effective as compared with younger individuals. 6 -8 Recently we demonstrated an aging-associated impairment in cardiac endothelial induction of platelet-derived growth factor (PDGF)-B that underlies the depression in senescent cardiac angiogenic function. 9 We speculated that delivery of young endothelial precursor cells (EPCs) may be employed to revitalize the PDGF-B pathway and reverse the decline in senescent cardiac angiogenic function. There is compelling evidence from our laboratory, 10, 11 as well as others, [12] [13] [14] [15] [16] [17] demonstrating that bone marrow-derived EPCs are recruited to angiogenic foci in the peripheral vasculature. Moreover, clinically, the impairment in these cells correlates with an increased risk of myocardial infarction, 18 suggesting that renewal of young EPC activity by bone marrow transplantation may restore senescent cardiac angiogenic function.
In the present study, we expand the previous findings, demonstrating that transplantation of young bone marrow restores the pathways critical for cardiac angiogenesis in the aging host. Moreover, this approach does not require ablation of the endogenous aging bone marrow and establishes a new concept in the treatment of aging-related diseases.
Materials and Methods

Molecular Studies
In order to determine the potential of bone marrow-derived EPCs to reconstitute cardiac myocyte-induced PDGF-B-mediated angiogenic function in aging mice, bone marrow cells were isolated from 3-and 18-month-old C57B1/6 mice (Harlan Sprague-Dawley, Indianapolis, Ind) and EPCs cultured, as previously described, 17 in DMEM supplemented with 10% fetal calf serum and 50 g/mL heparin, 100 g/mL streptomycin, and 500 g/mL penicillin (all from Sigma), and 10 ng/mL vascular endothelial cell growth factor, and 5 ng/mL fibroblast growth factor-2 (R&D Systems). The EPC cultures (initially PECAM negative) were expanded for 2 passages, confirmed by Di-Ac-LDL uptake and PECAM staining, and then plated into 12-well dishes (10 5 cells/well) (Costar). Cardiac myocytes (E15.5d) were isolated and plated in 12-mm 0.4-m pore transwells (10 5 cell/transwell) and then were transferred at different time points (0 to 48 hours) into 3-and 18-month-old bone marrow-derived EPCs seeded wells as previously described. 9, 19 As controls for myocyte-induced gene expression, cardiac microvascular endothelial cells were isolated from 3-and 18-month old C57B61/L mice and were cultured alone as well as with fetal cardiac myocytes for 48 hours as previously described. 9 At the termination of the cultures, total RNA was isolated from the EPC/endothelial cell wells and RT-PCR was performed. The following sets of oligonucleotides primers were employed: murine PDGF-B (forward) 5Ј-ATCGCCGAGTGCAAGACGCG-3Ј, (reverse) 5Ј-AAGCAC-CATTGGCCGTCCGA-3Ј; murine VEGF (forward) 5Ј-GGATCCAT-GAACTTTCTGCTGCTGTCTTGG-3Ј, (reverse) 5Ј-TTCTGGCTT-TGTCCTGTCTTTCTTTGG-3Ј; murine PECAM (forward) 5Ј-CAAGCGGTCGTGAATGACAC-3Ј; (reverse) 5Ј-CACTGCCTTGA-CTGTCTTAAG-3Ј; murine ␤-actin (forward) 5Ј-GTGGGC-CGCTCTAGGCACCAA-3Ј; (reverse) 5Ј-CTCTTTGATGTCAC-GCACGATTTC-3Ј.
Protein samples were isolated from additional EPC transwells cultured in the presence or absence of cardiac myocytes as previously described 9, 19 and were applied to Nunc Maxisorb plates (Roskilde) for 1 hour at room temperature. The samples were then washed with PBS 3 times, followed by blocking with 5% casein in PBS. Polyclonal antibodies to PDGF-B (1:300 dilution sc-7878, Santa Cruz Biotechnology) and PECAM (1:500 dilution 550274, BD Pharmigen) were then employed and developed with peroxidaselabeled donkey polyclonal antibodies to rabbit and rat IgG (1:1000, Jackson Immunoresearch Laboratories) and assayed as previously described. 9, 19 All studies were performed a minimum of 3 times.
Bone Marrow Transplantation
Bone marrow transplantation was performed as previously described. 20 Briefly, 3-and 18-month-old C57Bl/6 mice, as well as 3-month-old B6.129Sv-Gtrosa26 (Rosa-26) mice, 21 were euthanized, and tibias and femurs were removed and trimmed of muscle and extraossial tissue. All the cells in the Rosa-26 express LacZ; therefore, transplantation of the Rosa-26 bone marrow into the wild-type isogeneic senescent hosts facilitated the identification of the transplanted cells by X-gal staining. The bones were cut proximally and distally, and the bone marrow flushed with 2% bovine serum albumin in IDDM. The cellular pellets were washed with and resuspended in IDDM. The bone marrow cells were then injected into intact, unirradiated wild-type 18-month-old host C57Bl/6 mice by tail vein injection with 300 L of cells (3-monthold C57Bl/6: 10 7 cells, nϭ16; 10 6 , nϭ12; 10 5 , nϭ6; 18-month-old C57Bl/6, 10 7 , nϭ6; 3-month-old Rosa-26, 10 7 , nϭ6). The survival rates of all mice transplanted with exogenous bone marrow was 100%. Sets of mice receiving Rosa-26 bone marrow were euthanized 14 days after bone marrow transplantation, and the bone marrow was stained for ␤-galactosidase activity (X-gal, Fischer Scientific).
Cardiac Allograft Transplant Studies
To test the physiological actions of bone marrow transplantation and the recruitment of bone marrow-derived EPCs in cardiac angiogenic function, we employed a cardiac allograft model, which allows the assessment of strategies that restore cardiac angiogenic potential in aging mice while controlling the age of cardiac tissue being vascularized. In this model, which recapitulates the PDGF-mediated cardiac myocyte-endothelial cell communication and angiogenic induction, 19, 22, 23 neonatal C57Bl/6 (24-hour-old) murine hearts are transplanted into the pinnae of syngeneic host mice. In the senescent mice, the cardiac allografts are not vascularized due to an impairment in PDGF-B induction in the endothelial cells of the aging mice, and exogenous delivery of PDGF-AB specifically restores the angiogenic defect and promotes the engraftment of the transplanted cardiac tissue. 9 One week after bone marrow transplantation the mice received pinnal cardiac allografts to assess senescent cardiac angiogenic activity. Allograft viability was scored by pinnal and transplant integrity 1 week after engraftment, as we have previously described. 9 Pinnal electrocardiograms were recorded as previously described to further document the viability of the cardiac allografts. 24 Intact wild-type 3-and 18-month-old mice (nϭ8 each) served as positive and negative controls, respectively. Seven days after cardiac allograft transplantation, mice receiving Rosa-26 bone marrow were euthanized, and the exogenous cardiac tissue with surrounding pinnal tissue was sectioned and stained for ␤-galactosidase activity (X-gal, Fischer Scientific), von Willebrand factor (082, Dako), and PDGF-B (sc-7878, Santa Cruz Biotechnology). In addition to demonstrate the role of PDGF in the restoration of senescent cardiac angiogenic function, at the time of cardiac allograft transplantation, sets of older mice transplanted with 10 7 young bone marrow cells were treated with single subcutaneous pinnal injections of antibodies to neutralize the PDGF pathway (10 g in 20 L PBS, AB-20-NA, R&D Systems; nϭ7), or nonimmune rabbit IgG (10 g in 20 L PBS, AB-105-C, R&D Systems; nϭ7) as we have previously described. 9 Studies were performed in compliance with the Institutional Animal Care and Use Committee of Weill Medical College of Cornell University.
Results
Young Bone Marrow-Derived Endothelial Precursor Cells Mediate PDGF-B Cardiac Angiogenic Pathways
We speculated that bone marrow-derived EPCs of young mice may offer a novel means of reversing the impairment in PDGF-B induction that underlies the senescent dysregulation of cardiac angiogenic pathways. 9 To this end, we tested the capacity of young bone marrow-derived EPCs to reestablish the cardiac myocyte-PDGF-B endothelial pathways in the aged cardiac angiogenic environment. 9, 19 In vitro cardiac myocyte coculture assays revealed that PDGF-B expression was dynamically induced in the young, but not older, bone marrow-derived EPCs (Figure 1a) , resulting in the subsequent generation of PDGF-B protein (Figure 1b) . Moreover, unlike endothelial cells isolated from the murine cardiac microvasculature, 9 EPCs isolated from both the young and older bone marrow did not express VEGF, suggesting that restoration of PDGF-B induction by delivery of young bone marrow EPC may mediate the critical upstream molecular pathways required for the restoration of senescent cardiac angiogenic function. 
Transplanted Young Bone Marrow-Derived Endothelial Precursor Cells Home to Senescent Cardiac Angiogenic Foci
Based on the in vitro results, we tested the potential of young bone marrow-derived EPCs to home to sites of cardiac angiogenesis in the aging host. In order to develop an approach that would facilitate the future application of these studies to modulate intact vasculature function, we elected to transplant the bone marrow of young mice into intact, unirradiated older mice. To test ability of the young bone marrow to augment the population of aging murine bone marrow LacZ ϩ , Rosa-26 bone marrow was transplanted intravenously into intact isogeneic older mice 1 week before inducing cardiac angiogenesis. Analysis of these mice revealed that the genetically marked bone marrow (␤-galactosidase-positive) cells were recruited to and engrafted in the senescent bone marrow (Figure 2a) , suggesting that EPCs derived from donor cells could contribute to the endogenous response to angiogenic signals. Indeed, transplantation of neonatal wild-type cardiac allografts induced the recruitment of young bone marrow-derived EPCs, as evidenced by transgene-positive von Willebrand factor costaining endothelial cells integrated in the vasculature supplying the cardiac allografts, (Figures 2b through 2g) . Furthermore, the bone marrow-derived EPCs mediated the induction of PDGF-B (Figure 2h ), confirming the in vivo potential of the young cells to restore PDGF-B-dependent pathways in the aging vasculature.
Transplantation of Young Bone Marrow Rescues Senescent Cardiac Angiogenic Function
The aging-impaired cardiac angiogenic function was confirmed by the lack of cardiac allograft vascularization transplanted in the older mice (Figure 3a) , which is due to a dysregulation of the PDGF-B induction pathways in the senescent endothelium. 9 Based on the ability of the young bone marrow-derived EPCs to reconstitute PDGF-B induction in the presence of cardiac myocytes and their recruitment to cardiac angiogenic foci, we hypothesized that these cells could rescue cardiac angiogenic function in the aging mice. Remarkably, transplantation of bone marrow of 3-month-old mice into intact 18-month-old murine hosts maintained the viability and restored the function of the exogenous cardiac tissue (Figure 3a) . Transplantation with the bone marrow of 18-month-old mice failed to reverse the aging-associated decline in cardiac angiogenic function (Figure 3b ). The restoration of the senescent vascular function by the young bone marrow cells demonstrated a cellular dose-dependent response. Moreover the angiogenic response in the bone marrow-transplanted aging mice was specifically blocked by inhibition of PDGF (Figure 3b ), similar to results observed in young intact hosts in which neutralization of PDGF pathways prevented vascularization of cardiac tissue but not pulmonary allografts, 9 thus confirming the importance of PDGF in the young bone marrow EPC-mediated restoration of senescent cardiac angiogenic function in vivo.
Discussion
The present studies demonstrate that reconstitution of bone marrow-derived EPC function can specifically promote cardiac angiogenic function in the aging host. Young bone marrowderived EPCs are capable of populating the intact, senescent bone marrow, homing to sites of cardiac angiogenic induction, and restoring pathways required for vascular function.
Our findings represent a significant advance in defining the mechanistic roles of bone marrow-derived EPCs in the peripheral vasculature. Although previous studies have demonstrated the incorporation of bone marrow-derived EPCs into the peripheral vascular, these studies did not elucidate the relevant physiological contribution of the exogenous endothelium in angiogenic function. 10, 15, 25, 26 Recent studies have revealed that direct injection of bone marrow cells into cardiac tissue promotes vascular activity 26, 27 ; however, the molecular mechanisms of the specific cellular mediators of this function remain to be defined. Our results demonstrate that bone marrow-derived EPCs recruited from the trans- 
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planted young bone marrow cells restore PDGF-mediated autocrine as well as other potentially critical autocrine and paracrine pathways required for cardiac angiogenic function. Moreover, the present studies were performed in unirradiated, wild-type aged mice, demonstrating the potential utility of transplanting unfractionated or specific linages of young bone marrow cells without ablating the host bone marrow to restore and/or augment the function of critical cell populations in the senescent bone marrow. Transplantation of young bone marrow cells that give rise to EPC populations offers a novel means of delivering angiocompetent endothelial cells to sites of cardiac angiogenesis. Furthermore, as the functional capacity of the bone marrowderived cells is governed by the cardiac myocyte/myocardial environment, genetic modifications of these cells may be potentially directed toward the expression of particular genes in order to target specific actions in the aging cardiac vascular bed. Indeed, as the older EPCs lack the capacity to express PDGF-B in the presence of cardiac myocytes, further studies aimed at elucidating the impairment in these cells coupled with the development of approaches to genetically engineer stem cells in vivo may allow the development of autologous approaches to augment senescent vascular function and reduce the extent of myocardial infarctions in aging hearts. Similarly the delivery of angiocompetent, PDGF-B-expressing EPCs may also provide a means of targeting vascular/endothelial dysfunction induced by conditions directly related to the biology of aging, 28 -30 as well as conditions that may exacerbate these changes, such as diabetes. 31, 32 The role of young bone marrow-derived EPCs is likely not restricted to the restoration of PDGF pathways and cardiac angiogenic function in the aging host and may have a therapeutic role in reversing the aging-associated impairment in endothelial function, 30 as well as modulating hemostatic and rheologic changes in the senescent vascular. [33] [34] [35] Overall, restoration of bone marrow-derived EPC function offers a foundation for the development of strategies specifically tailored for the treatment of cardiovascular disease in older individuals. 
